Etoposide and Non-hodgkin's lymphoma refractory - a phase IV clinical study of FDA data

Summary:

Non-hodgkin's lymphoma refractory is reported as a side effect among people who take Etoposide (etoposide), especially for people who are male, 10-19 old, have been taking the drug for 1 - 6 months also take Cyclophosphamide, and have Non-hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Non-hodgkin's lymphoma refractory when taking Etoposide. It is created by eHealthMe based on reports of 77,756 people who have side effects when taking Etoposide from the FDA, and is updated regularly.

What is Etoposide?

Etoposide has active ingredients of etoposide. eHealthMe is studying from 77,815 Etoposide users. Check the latest studies of Etoposide.

What is Non-hodgkin's lymphoma refractory?

Non-hodgkin's lymphoma refractory (refractory malignant (cancer) cells form in the lymph system) is found to be associated with 11 drugs and 15 conditions by eHealthMe. Check the latest studies of Non-hodgkin's lymphoma refractory.

On Jul, 12, 2026

77,756 people reported to have side effects when taking Etoposide.
Among them, 14 people (0.02%) have Non-hodgkin's lymphoma refractory.

$Could Etoposide cause Non-hodgkin's lymphoma refractory?$

Among these 14 people:

How long have people been on Etoposide when they have Non-hodgkin's lymphoma refractory? *

What is the gender of people who have Non-hodgkin's lymphoma refractory when taking Etoposide? *

female: 11.11 %
male: 88.89 %

What is the age of people who have Non-hodgkin's lymphoma refractory when taking Etoposide? *

What are other drugs people take besides Etoposide? *

What are other side effects people have besides Non-hodgkin's lymphoma refractory? *

Disease Progression: 6 people, 42.86%
Tumor: 3 people, 21.43%
C-Reactive Protein Increased: 3 people, 21.43%
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system): 3 people, 21.43%
Drug Ineffective: 3 people, 21.43%
Gastrointestinal Perforation (hole in the digestive tract): 3 people, 21.43%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 21.43%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 3 people, 21.43%
Leukopenia (less number of white blood cells in blood): 3 people, 21.43%
Spinal Cord Compression: 3 people, 21.43%

What are the existing conditions these people have? *

Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 8 people, 57.14%
Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 2 people, 14.29%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 2 people, 14.29%
T-Cell Lymphoma Refractory (a t cell cancer resistant to treatment): 1 person, 7.14%
High Grade B-Cell Lymphoma Burkitt-Like Lymphoma (cancer of b cells): 1 person, 7.14%
Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Etoposide and have Non-hodgkin's lymphoma refractory?

- Check whether Non-hodgkin's lymphoma refractory is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Etoposide:

Etoposide (77,815 reports)

Browse all side effects of Etoposide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Non-hodgkin's lymphoma refractory:

Non-hodgkin's lymphoma refractory (11 drugs)

Browse all the conditions that are associated with Non-hodgkin's lymphoma refractory:

Non-hodgkin's lymphoma refractory (15 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on etoposide (the active ingredients of Etoposide) and Etoposide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.